Mechanistically, circBA9.3 strengthened the antiapoptotic properties of K562 cells and upregulated the levels of both ABL1 and BCR-ABL1 proteins to reduce the sensitivity of leukemia cells to TKIs, thereby promoting resistance against TKI therapy [45]. The gene discussed is ABL1; the disease is leukemia.